Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit HIGH POINT, N.C.
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 16, 2018-- vTv Therapeutics Inc.
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 30, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018 , and provided an update on recent achievements and upcoming events. “Since our announcement regarding the topline results from
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
HIGH POINT, N.C. --(BUSINESS WIRE)--May 31, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program
HIGH POINT, N.C. --(BUSINESS WIRE)--May 15, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial and operational results for the first quarter that ended March 31, 2018 . “We continue to make progress on all of our major programs,” said Steve Holcombe , chief executive officer, vTv
Subgroup of Mild Alzheimer’s Patients in Part A of Phase 3 STEADFAST Study Demonstrated Positive Benefit HIGH POINT, N.C. --(BUSINESS WIRE)--May 9, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary